Objectives: To report interim 1-year results from a 3-year surveillance study evaluating safety, efficacy, and persistence of long-term mirabegron for overactive bladder (OAB).
| INTRODUCTION
Overactive bladder (OAB) is a common syndrome with a significant impact on quality of life. 1, 2 It is estimated that >500 million people worldwide will experience OAB symptoms by 2018, with the greatest proportion of patients residing in Asia. 3 Historically, oral antimuscarinic agents have been the mainstay of OAB therapy, although the associated side-effects (including dry mouth and constipation) further affect quality of life and adversely affect treatment adherence. 4, 5 Treatment persistence of OAB medication is lower than for any other chronic disease therapy, 6 with a number of studies demonstrating poor treatment persistence with antimuscarinics. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] As such, OAB treatments with alternative mechanisms of action and improved tolerability are desirable.
Mirabegron is the first β 3 -adrenoceptor agonist for the treatment of OAB. During the pivotal phase 3 trials conducted in Europe, Australia, and North America, 12 weeks of mirabegron treatment had significant improvements over placebo with regards to the co-primary endpoints of incontinence episodes and micturitions per 24 hours. [19] [20] [21] Mirabegron was generally well-tolerated during the clinical trials conducted to date (reviewed by Chapple et al. 22, 23 ).
Mirabegron was approved for treatment of OAB in Japan in 2011. Subsequent clinical studies conducted in Japan confirmed the efficacy observed in the aforementioned pivotal studies. [24] [25] [26] In addition to these clinical trials, a post-marketing study provided real-world data from 9795 OAB patients initiating mirabegron, with mirabegron deemed "effective" in 80.7% of patients, with 63.6% of patients achieving the minimal clinically important change (MCIC) of a three OAB severity score (OABSS)-point improvement after 12 weeks. 27, 28 In this clinical setting, mirabegron was well-tolerated, with no unanticipated adverse drug reactions (ADR).
Such real-world data are critical to more fully understand the safety and effectiveness of a drug outside the constraints of formal clinical trials, and can provide additional information on how a drug is actually being used in clinical practice. This is of particular relevance for mirabegron, which may be used in a wide variety of patients, potentially over long periods of time. Furthermore, several studies have provided evidence that mirabegron persistence is greater than that for antimuscarinic OAB medications. [29] [30] [31] Equivalent data are currently lacking for Japanese patients in the published literature. In a small study of 72 Japanese patients, 29% of patients prescribed mirabegron continued treatment for 12 months. 32 In a study of female Japanese patients, the 12-month persistence rate was 12% for 76 patients receiving mirabegron, compared with 20% of 72 patients receiving solifenacin. 33 In contrast, an as yet unpublished retrospective cohort study of 3872 Japanese patients demonstrated higher persistence among patients receiving mirabegron compared with solifenacin, fesoterodine, tolterodine, imidafenacin, and propiverine. 34 Other currently unpublished studies conducted at single institutions have demonstrated that mirabegron persistence was significantly higher compared with anticholinergic agents. 35, 36 In Japan, manufacturing/marketing authorization holders must perform post-marketing surveillance on new drugs so that efficacy and safety can be reconfirmed on re-examination by the Ministry of Health, Labour, and Welfare (MHLW) for a specified period after marketing approval. The data reported herein are from one of four such surveillance studies comprising the mirabegron post-marketing surveillance program. Two of these studies have been published to date, with the final study in progress. 28, 37 The objective of the current study was to evaluate the safety and efficacy of long-term use of mirabegron, and to determine treatment persistence. Reported herein are the interim 1-year results from this 3-year surveillance study.
| METHODS
The surveillance study was conducted in accordance with the Good Post-Marketing Study Practice (GPSP) standards of the MHLW. A total of 1000 patients were registered to meet a sample size calculation of 300 patients with an observation period of at least 1 year.
Physicians were instructed to follow the prescribing information for mirabegron in Japan, although dosing was ultimately at physician discretion. 39 The usual mirabegron adult dose is 50 mg once daily, 40 and were judged to have OAB based on the OABSS (OABSS question 3 ≥2 points at baseline and total OABSS ≥3 points at baseline), who were given mirabegron in accordance with the dosing regimen, and who were assessed for OABSS at baseline and final assessment without missing data.
With regards to safety, data on adverse events (AE; including ADR and abnormal findings from laboratory/other tests) during or after mirabegron treatment were collected. AE were analyzed by time of onset (<1 month, ≥1-<3 months, ≥3-<6 months, ≥6-<9 months, ≥9 months-<1 year, and ≥1 year-<1 year 3 months) with only the first occurrence counted if the AE was experienced more than once.
In terms of efficacy, changes in OAB symptoms after 1 year of treatment (or at discontinuation) in comparison with the symptoms at the start of treatment were assessed; treatment was deemed "effective,"
"not effective" or "not assessable." Response to treatment (disappearance of OAB) was defined as a reduction to <2 points on OABSS question 3 or to <3 points on total OABSS from baseline. An MCIC in the OABSS analysis set was defined as OABSS improvement ≥3
points from baseline. 27 For residual urine volume and OABSS, changes from baseline at each observation point were calculated and compared using Wilcoxon's signed rank test.
The treatment persistence rate was calculated using the Kaplan-Meier method. Patients who continued the study drug during the first year of treatment or who had incomplete visits during the study were censored at the final assessment. Reasons for treatment discontinuation were collected and analyzed by time of discontinuation (<1 month, ≥1-<3 months, ≥3-<6 months, ≥6-<9 months, ≥9 months-<1 year, and ≥1 year-<1 year 3 months). Analysis of treatment discontinuation by sex (male vs female), age (<65 years vs ≥65 years), and therapy status (monotherapy vs combination therapy, defined as treatment with at least one OAB agent other than mirabegron during the 1-year observation period) was conducted using log-rank test.
3 | RESULTS
| Patients
Data were collected from 1252 patients from 177 institutions, of whom 1139 patients were included in the safety analysis set and efficacy analysis set ( Figure 1 ).
Baseline characteristics are listed in Table 1 . Mean age was 71.9 years, with the majority (79.7%) of patients aged ≥65 years. Similar proportions of patients had OAB disease duration in each of the categories defined. Most patients had OAB of moderate severity (60.0%). The majority of patients (67.6%) had concurrent diseases, the most common of which were prostatic hyperplasia (31.1%), high blood pressure (15.2%), and hypertension (9.7%). In the 615 patients (54.0%) receiving concomitant medications, the most common medications were naftopidil (10.4%, n = 118), silodosin (9.4%, n = 107), and tamsulosin hydrochloride (8.0%, n = 91). Only 4.2% of patients (n = 48) were receiving another drug (in addition to mirabegron) for the treatment of OAB: 25 were receiving solifenacin; 15, imidafenacin; seven, propiverine; three, tolterodine; and two, fesoterodine. Renal impairment was present in 55 patients (4.8%; 50 with mild and 5 with moderate severity) and hepatic impairment in 12 patients (1.1%; 11 with mild and one with moderate severity).
The majority of patients were receiving mirabegron 50 mg at the start of the study (84.5%), which remained the maximum daily dose (87.8%) and mean daily dose (83.5%) in most patients (Table 2 ).
| Safety
A total of 81 ADR were observed in 72 of 1139 patients in the safety analysis set (Table 3 ). The incidence of ADR (the percentage of (n = 1252) † FIGURE 1 Patient disposition. †Analysis was performed on the clinical report forms at 1 year from 1252 patients whose forms were collected. ‡Including duplicated patients. §Patients whose Overactive Bladder Symptom Score (OABSS) question 3 was <2 points at baseline or total OABSS was <3 points at baseline. ¶Abnormal bladder (bladder cancer, bladder calculus, or interstitial cystitis [bladder pain syndrome]), perivesical abnormalities (endometriosis etc.), prostatic/urethral abnormalities (prostate cancer or urethral calculus), urinary tract genital infections (bacterial cystitis, prostatitis, or urethritis), or other (urinary retention, polyuria, or psychogenic pollakiuria). 40 † †Patients with moderate hepatic impairment as determined by Child-Pugh score or/and MHLW classification criteria for the severity of adverse drug reactions. 41 Patients with severe renal impairment as determined by MHLW classification criteria for the severity of adverse drug reactions 41 
| Efficacy
Of the 1091 evaluable patients in the efficacy analysis set, mirabegron was deemed "effective" in 883 at 1 year of treatment (or at discontinuation), resulting in an efficacy rate of 80.9%.
Of the 502 patients comprising the OABSS analysis set, OABSS (mean ± SD) at baseline was 9.0 ± 2.35 points. The total OABSS (mean ± SD) was decreased with statistical significance at 3 months, 6 months, and 1 year of treatment, and at final assessment 
| Treatment persistence
The treatment persistence rates, according to Kaplan-Meier analysis, were 84.8% at 3 months, 77.6% at 6 months, and 66.0% at 1 year of treatment ( Figure 4A ). A total of 631 patients discontinued mirabegron treatment during the first year of treatment, with approximately equal proportions having incomplete visits (49.4%) and discontinuation (50.6%) during the observation period ( Table 4 ). The most common reason for discontinuation during the observation period was "no The Kaplan-Meier treatment persistence rates at 1 year of treatment were similar for male and female patients (66.4%, n = 564 and 65.6%, n = 575, respectively; log-rank test: P = 0.601; Figure 4B ). A total of 282 male patients and 349 female patients discontinued mirabegron during the first year of treatment. The most common reason for discontinuation during the observation period in male patients was "no change or aggravated symptoms" (22.7%, 64/282 patients discontinuing treatment); in female patients the most common reasons were "no change or aggravated symptoms" and "patient's request (excluding AE)" (both 15.2%, 53/349; Table 5 ). Whereas the percentage of patients who discontinued treatment due to "no change or aggravated symptoms" was higher in female than male patients within the first month of treatment, the difference between the sexes was reversed after the first month.
Patients aged ≥65 years had significantly higher Kaplan-Meier treatment persistence rates at 1 year of treatment (67.3%; n = 908) compared with patients <65 years (59.8%; n = 231; log-rank test: P = 0.032; Figure 4C ). A greater proportion of patients <65 years discontinued mirabegron treatment due to incomplete visits during the observation period (58.4%, 94/161) than discontinued during the observation period (41.6%, 67/161), whereas the proportions were more similar in patients ≥65 years (46.4%, 218/470 and 53.6%, 252/470, respectively; Table 6 ). "No change or aggravated symptoms" was the most common reason for discontinuation during the observation period for both patients <65 and ≥65 years (15.5%, 25/161 and 19.6%, 92/470, respectively). Patients aged ≥65 years discontinued treatment more frequently due to "onset of AE" than patients <65 years (8.9%, 42/470 vs 3.1%, 5/161, respectively).
The Kaplan-Meier treatment persistence rate at 1 year was statistically significantly higher among patients receiving combination therapy 
Abbreviations: ADR, adverse drug reaction. a Japanese Medical Dictionary for Regulatory Affairs version 19.0 (MedDRA). Events with >1 occurrence during observation period. When there was more than one ADR in the same patient, the events were summarized in a duplicated manner but duplicates were excluded from the cumulative total.
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FIGURE 2 Residual urine volume change from baseline at each observation point (safety analysis set). n = 338 at 3 months, n = 237 at 6 months, n = 212 at 1 year, and n = 464 at final assessment. Data given as mean ± SD FIGURE 3 Change in overactive bladder symptom score (OABSS) from baseline at each observation time point (OABSS analysis set). ***P < 0.001. n = 370 at 3 months, n = 286 at 6 months, n = 271 at 1 year, and n = 502 at final assessment. Data given as mean ± SD (80.9%; n = 48) compared with monotherapy (65.7%; n = 1048; logrank test: P = 0.037). The comparatively low number of patients receiving combination therapy prevented any further consideration.
| DISCUSSION
This is the first extensive, multicenter study on mirabegron persistence in Japan, with the interim 1-year results reported herein demonstrating that treatment discontinuation rates and the reasons for discontinuation vary according to patient age and sex.
The frequency of ADR was low (6.3%), with the greatest number occurring during the first month of treatment. The frequency of ADR did not show a tendency to increase with longer treatment duration.
The most common ADR (constipation, dysuria, and residual urine volume increased) are consistent with previous studies. 22 There were six ADR, of which only one event of urinary retention was deemed to be possibly related to mirabegron treatment. The mean change in residual urine volume did not show a tendency to increase from baseline to 1 year, although physicians should remain vigilant for the occurrence of these ADR.
The mirabegron efficacy rate at 1 year (or at the time of treatment discontinuation) was high (80.9%), with the significant improvement in OABSS achieved by month 3 maintained through 1 year.
More than half (56.0%) of patients responded to treatment and 65.8%
achieved the MCIC (OABSS decreased by ≥3 points at 1 year or final assessment). These findings are consistent with the results of a previous 12-week mirabegron post-marketing study, 28 and the maintenance of overall mirabegron effectiveness over 1 year is also consistent with other long-term studies conducted in Japan and Europe. 24, 42 Mirabegron treatment persistence rates were high: 77.6% at 6 months of treatment and 66.0% at 1 year of treatment, which is even higher than has been observed in previous studies. A retrospective case review study and a prospective case series carried out in the UK demonstrated that mirabegron treatment persistence was 48% at 6 months 43 and 25% at 12 months, respectively. 44 Similarly, in the aforementioned claims database studies in the USA and Canada, treatment persistence was 35% at 6 months, 30 and 32% at 12 months, respectively. 31 The results, however, are similar to the 63% 12-month persistence rate reported in a currently unpublished Japanese case series 35 and with the 84% 1-5-month persistence rate in an as yet unpublished prospective, observational study in Europe. 45 The higher persistence rates may reflect differences between Japanese patients and/or health-care system compared with other countries, or the prospective study design, which may have affected patient attitudes and have involved more frequent follow-ups than would be usual in normal clinical practice.
The most frequent reason for the discontinuation of mirabegron treatment was "no change or aggravated symptoms." Although direct comparisons are inappropriate, this is broadly consistent with previous studies of mirabegron treatment persistence in the UK (in which "lack of efficacy" was the most common reason) 43, 44 and in Japan (in which "ineffectiveness" was the most common reason). 36 Furthermore, in a prospective trial of mirabegron versus solifenacin in female patients with OAB, discontinuation due to "lack of efficacy" was significantly more frequent for mirabegron compared with solifenacin (36.8% vs 5.6%, respectively), whereas discontinuation due to "side-effects" was significantly more frequent for solifenacin compared with mirabegron (27.3% vs 7.9%, respectively). 33 In a post-marketing study of solifenacin, "symptom remission" was the most frequent reason for treatment discontinuation during the 2-year observation period, which may reflect the high efficacy rate for solifenacin during the same period of this study (84.7%). 46 The mirabegron treatment persistence rate was higher in patients aged ≥65 years compared with patients aged <65 years, although there was no difference in persistence rates between male and female patients. "No change or aggravated symptoms" remained the most common reason for discontinuation in male and female patients and in patients aged <65 and ≥65 years. In the two aforementioned studies of mirabegron treatment persistence in the USA 30 and Canada, 31 mirabegron persistence tended to be significantly higher in elderly patients in both studies, consistent with the present results. In the present study, patients aged ≥65 years discontinued treatment more frequently due to "onset of AE" than patients <65 years. The importance of understanding treatment persistence in elderly patients is of particular importance in the Japanese population, which has >25% of the population aged ≥65 years. 47 Whereas there was no difference in mirabegron persistence between male and female patients in the US study, 30 male patients were more likely to discontinue mirabegron treatment than female patients in the Canadian study. 31 Further research is needed to understand the reasons for the differences in persistence between different patient groups.
Previous studies have reported that mirabegron persistence is higher than for antimuscarinic agents, although, to date, data from Japan have been from only relatively small, single-center studies. [30] [31] [32] 35, 36 The present surveillance study represents the most extensive to date on mirabegron persistence in the Japanese popula- 
| CONCLUSION
In this interim 1-year report of a 3-year surveillance study, long-term treatment of OAB with mirabegron was well-tolerated with effectiveness maintained through 1 year. Mirabegron treatment persistence was higher than has been previously reported, and was greater in patients aged ≥65 years compared with those <65 years. 
